NCT00061568View on ClinicalTrials.gov

Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

July 16, 2004

Primary Completion Date

January 20, 2023

Study Completion Date

January 31, 2026

Conditions
Congenital Hemolytic AnemiaSickle Cell Disease
Interventions
PROCEDURE

Peripheral blood hematopoietic progenitor cell (PBPC) transplant

Peripheral blood hematopoietic progenitor cell (PBPC) transplant

DRUG

Alemtuzumab

Alemtuzumab

PROCEDURE

Peripheral blood hematopoietic progenitor cell Apheresis

Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis

DRUG

Sirolimus

Sirolimus

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00061568 - Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias | Biotech Hunter | Biotech Hunter